Iris To

438 total citations
15 papers, 127 citations indexed

About

Iris To is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Iris To has authored 15 papers receiving a total of 127 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 9 papers in Genetics and 7 papers in Oncology. Recurrent topics in Iris To's work include Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Iris To is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Iris To collaborates with scholars based in United States, Canada and Australia. Iris To's co-authors include Lihua E. Budde, Sarit Assouline, Matthew J. Matasar, Matthew Ku, Nancy L. Bartlett, Pratyush Giri, Michael C. Wei, Elicia Penuel, Nilanjan Ghosh and Manali Kamdar and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Lymphoma Myeloma & Leukemia.

In The Last Decade

Iris To

10 papers receiving 126 citations

Peers

Countries citing papers authored by Iris To

Since Specialization

Citations

This map shows the geographic impact of Iris To's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris To with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris To more than expected).

Fields of papers citing papers by Iris To

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris To. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris To. The network helps show where Iris To may publish in the future.

Co-authorship network of co-authors of Iris To

This figure shows the co-authorship network connecting the top 25 collaborators of Iris To. A scholar is included among the top collaborators of Iris To based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris To. Iris To is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	MCL-1493: Fixed-Duration Outpatient Subcutaneous Mosunetuzumab + Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL) 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Michael Wang, Manali Kamdar, Sarit Assouline, Nilanjan Ghosh, Seema Naik, (unknown), (unknown), Thomas Ollila, Daniel J. Hodson, Dipenkumar Modi, Mariana Bastos‐Oreiro, (unknown), Iris To, (unknown), Jue Wang, Hao Wu, (unknown), Connie Lee Batlevi, Michael C. Wei, Lihua E. Budde	0
2	Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL). 2024 ·Journal of Clinical Oncology ·Sarit Assouline, Lihua E. Budde, Julio C. Chávez, Catherine Diefenbach, Kathleen Dorritie, Nilanjan Ghosh, Adam J. Olszewski, Izidore S. Lossos, Amitkumar Mehta, Dipenkumar Modi, Seema Naik, Stephen D. Smith, (unknown), (unknown), Hao Wu, Connie Lee Batlevi, Iris To, Michael C. Wei, Manali Kamdar	0
3	Mosunetuzumab With Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Sarit Assouline, Lihua E. Budde, Julio C. Chávez, Catherine Diefenbach, Kathleen Dorritie, Nilanjan Ghosh, Adam J. Olszewski, Izidore S. Lossos, Amitkumar Mehta, Dipenkumar Modi, Seema Naik, Stephen D. Smith, (unknown), (unknown), Hao Wu, Connie Lee Batlevi, Iris To, Michael C. Wei, Manali Kamdar	1
4	IBCL-335 Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After ≥2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Stephen J. Schuster, Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar, Sarit Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y. Cheah, (unknown), Keith Fay, Loretta J. Nastoupil, Michael C. Wei, (unknown), Iris To, Jiangeng Huang, Antonia Kwan, Elicia Penuel, Lihua E. Budde	0
5	Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data 2024 ·Blood ·Lihua E. Budde, Adam J. Olszewski, (unknown), (unknown), Connie Lee Batlevi, (unknown), Iris To, Michael C. Wei, (unknown), Victor M. Orellana‐Noia, Lisa Musick, (unknown), Navdeep Pal, Ashwini Shewade, Jason R. Westin	0
6	Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After ≥2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Stephen J. Schuster, Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar, Sarit Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y. Cheah, (unknown), Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, Elicia Penuel, Lihua E. Budde	0
7	Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Matthew J. Matasar, Nancy L. Bartlett, Mazyar Shadman, Lihua E. Budde, Ian W. Flinn, Gareth P. Gregory, Won Seog Kim, Georg Heß, Dima El‐Sharkawi, Catherine Diefenbach, Huang Huang, Iris To, (unknown), (unknown), Antonia Kwan, Sarit Assouline	10
8	Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study 2023 ·Blood ·Michael Wang, Sarit Assouline, Manali Kamdar, Nilanjan Ghosh, Seema Naik, (unknown), Julio C. Chávez, Ting Jia, (unknown), Ling‐Yuh Huw, Jing Jing, (unknown), Iris To, Connie Lee Batlevi, Michael C. Wei, Lihua E. Budde	18
9	Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study 2023 ·Blood ·Stephen J. Schuster, Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar, Sarit Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y. Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, Elicia Penuel, Lihua E. Budde	14
10	Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation 2023 ·Blood ·Chan Y. Cheah, Sarit Assouline, Ross Baker, Nancy L. Bartlett, Dima El‐Sharkawi, Pratyush Giri, Matthew Ku, Stephen J. Schuster, Matthew J. Matasar, John Radford, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, Lihua E. Budde	9
11	Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study 2022 ·Blood ·Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, (unknown), Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, (unknown), Iris To, Huang Huang, (unknown), Elicia Penuel, Lihua E. Budde	21
12	Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study 2022 ·Blood ·Adam J. Olszewski, Lihua E. Budde, (unknown), Nilanjan Ghosh, Manali Kamdar, Izidore S. Lossos, Catherine Diefenbach, Waleed Sabry, Kathleen Dorritie, Ling‐Yuh Huw, (unknown), Ting Jia, Hao Wu, Iris To, Michael C. Wei, Sarit Assouline	12
13	Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL). 2021 ·Journal of Clinical Oncology ·Lihua E. Budde, Nilanjan Ghosh, Julio C. Chávez, Izidore S. Lossos, Amitkumar Mehta, Kathleen Dorritie, Manali Kamdar, (unknown), (unknown), Maria Hristopoulos, Ling‐Yuh Huw, Carol O’Hear, Yasuhiro Oki, Iris To, Catherine Diefenbach	14
14	ABCL-351: Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Elizabeth Budde, Nilanjan Ghosh, Julio C. Chávez, Izidore S. Lossos, Amitkumar Mehta, Kathleen Dorritie, Manali Kamdar, (unknown), (unknown), Maria Hristopoulos, Ling‐Yuh Huw, Carol O’Hear, Yasuhiro Oki, Iris To, Catherine Diefenbach	1
15	Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts 2020 ·Blood ·Matthew J. Matasar, Chan Y. Cheah, Dok Hyun Yoon, Sarit Assouline, Nancy L. Bartlett, Matthew Ku, Pratyush Giri, Anna Johnston, Ian W. Flinn, André Goy, Dimitrios Tzachanis, Carol O’Hear, Shen Yin, Iris To, (unknown), Chi‐Chung Li, Brendan C. Bender, Elicia Penuel, Huang Huang, Lihua E. Budde	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact